经颈动脉血运重建治疗颈内动脉狭窄的早期与晚期结局:系统综述与Meta分析
汇总30天死亡率为0.7%,卒中率1.4%,卒中/TIA率2.0%,技术成功率97.6%。
要点
- TCAR术后30天卒中/TIA率为2.0%,死亡率0.7%,技术成功率97.6%。
- 症状性患者早期卒中/TIA风险显著高于无症状患者(OR 1.99)。
- 随访3-40个月再狭窄率4%,死亡/卒中率4.5%。
核心结论
- TCAR的早期和晚期结局良好,但症状性患者早期脑血管事件风险更高。
- 需要更多前瞻性对照研究来验证TCAR作为既定替代治疗技术的地位。
研究设计与样本
- 系统综述与Meta分析,检索Medline、Embase、Scopus和Cochrane Library数据库,纳入截至2020年9月在线发表的研究。
- 采用随机效应模型汇总数据,并根据Newcastle-Ottawa量表评估研究质量。
主要发现
- 汇总30天死亡率为0.7%(n=32,95%CI 0.5-1.0)。
- 汇总30天卒中率为1.4%(n=62,95%CI 1.0-1.7),30天卒中/TIA率为2.0%(n=92,95%CI 1.4-2.7)。
- 汇总技术成功率为97.6%(95%CI 95.9-98.8)。
- 颅神经损伤率为1.2%(95%CI 0.7-1.9,n=14,来自10项研究),早期心肌梗死率为0.4%(95%CI 0.2-0.6,n=16,来自17项研究),血肿/出血率为3.4%(95%CI 1.7-5.8,n=135,来自10项研究),其中三分之一需引流或干预。
关键数值与推荐
- 纳入标准为报告TCAR术后30天死亡率和卒中/TIA率的研究。
临床怎么用
- TCAR可作为颈动脉内膜剥脱术和经股动脉颈动脉支架置入术的替代方案,早期和晚期结局良好。
- 对于症状性患者,应充分评估早期卒中/TIA风险,并加强围手术期管理。
局限性
- 需要更多前瞻性对照研究来验证TCAR作为既定替代治疗技术的地位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Transcarotid/transcervical revascularisation (TCAR) is an alternative to carotid endarterectomy (CEA) and transfemoral carotid stenting (tfCAS). This review aimed to evaluate pooled data on patients undergoing TCAR. DATA SOURCES: Medline, Embase, Scopus, and Cochrane Library databases were used. REVIEW METHODS: This systematic review was conducted under Systematic Reviews and Meta-Analysis guidelines. Eligible studies (published online up to September 2020) reported 30 day mortality and stroke/transient ischaemic attack (TIA) rates in patients undergoing TCAR. Data were pooled in a random effects model and weight of effect for each study was also reported. Quality of studies was evaluated according to Newcastle - Ottawa scale. RESULTS: Eighteen studies (three low, seven medium, and eight high quality) included 4 852 patients (4 867 TCAR procedures). The pooled 30 day mortality rate was 0.7% (n = 32) (95% confidence interval [CI] 0.5 - 1.0), 30 day stroke rate 1.4% (n = 62) (95% CI 1.0 - 1.7), and 30 day stroke/TIA rate 2.0% (n = 92) (95% CI 1.4 - 2.7). Pooled technical success was 97.6% (95% CI 95.9 - 98.8). The cranial nerve injury rate was 1.2% (95% CI 0.7 - 1.9) (n = 14; data from 10 studies) while the early myocardial infarction (MI) rate was 0.4% (95% CI 0.2 - 0.6) (n = 16; data from 17 studies). The haematoma/bleeding rate was 3.4% (95% CI 1.7 - 5.8) (n = 135; data from 10 studies), with one third of these cases needing drainage or intervention. Within a follow up of 3 - 40 months the restenosis rate was 4% (95% CI 0.1 - 13.1) (data from nine studies; n = 64/530 patients) and death/stroke rate 4.5% (95% CI 1.8 - 8.4) (data from five studies; n = 184/3 742 patients). Symptomatic patients had a higher risk of early stroke/TIA than asymptomatic patients (2.5% vs. 1.2%; odds ratio 1.99; 95% CI 1.01 - 3.92); p = .046; data from eight studies). CONCLUSION: TCAR is associated with promising early and late outcomes, with symptomatic patients having a higher risk of early cerebrovascular events. More prospective comparative studies are needed in order to verify TCAR as an established alternative treatment technique.
引用
- Galyfos GC, Tsoutsas I, Konstantopoulos T, et al. Editor's Choice - Early and Late Outcomes after Transcarotid Revascularisation for Internal Carotid Artery Stenosis: A Systematic Review and Meta-Analysis. Eur J Vasc Endovasc Surg. 2021. PMID: 33674158. doi:10.1016/j.ejvs.2021.01.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。